{"id":"NCT03734991","sponsor":"Scynexis, Inc.","briefTitle":"Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303)","officialTitle":"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-01-04","primaryCompletion":"2019-08-21","completion":"2019-09-04","firstPosted":"2018-11-08","resultsPosted":"2021-09-08","lastUpdate":"2021-09-08"},"enrollment":376,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Candida Vulvovaginitis"],"interventions":[{"type":"DRUG","name":"Ibrexafungerp","otherNames":["SCY-078"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Ibrexafungerp (SCY-078)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a Phase 3, randomized, multicenter, double-blind, placebo-controlled study to evaluate the efficacy and safety of oral Ibrexafungerp (SCY-078) compared to placebo in female subjects 12 years and older with AVVC.","primaryOutcome":{"measure":"Clinical Cure (Complete Resolution of Signs and Symptoms)","timeFrame":"Day 8-14","effectByArm":[{"arm":"Ibrexafungerp (SCY-078)","deltaMin":95,"sd":null},{"arm":"Placebo","deltaMin":28,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":25,"countries":["United States"]},"refs":{"pmids":["36255448"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":247},"commonTop":["Diarrhoea","Nausea","Headache","Bacterial vaginosis","Abdominal pain"]}}